H1 Unveils New Brand on the Heels of Significant Financial, Customer and Product Capabilities Growth
With a refined mission to connect the world with the right doctors, new acquisition and enhanced global data solutions, H1...
Pharmaceutical
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients
A Multicenter Open Label Study of QRX003 Topical Lotion in Netherton Syndrome Patients Who Are Currently Receiving Systemic Biologic Therapy.ASHBURN,...
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel...
SteraMist to be Used in a Global Influenza Vaccine Facility in Australia
Company Continues To See Strong Bookings and A Robust Pipeline For Its Custom Engineered Systems in The Life Science SectorFREDERICK,...
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
Figure 1 SARS-COV-2 50% Tissue Culture Infectious Dose (TCID50) measurement in response to treatment with R327 in Syrian golden hamsters....
Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
Vistin Pharma ASA: Invitation to Q3 2022 conference call
Oslo, Norway, 18 October 2022 Vistin Pharma ASA will release its third quarter and YTD 2022 results on Wednesday 26th of...
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 -...
ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site
Immix Biopharma, Inc. (NASDAQ:IMMX) ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma...
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigorWALTHAM, Mass., Oct. 18, 2022 (GLOBE...
PETVIVO HOLDINGS, INC. TO PRESENT AT LD MICRO MAIN EVENT XV
PetVivo Holdings, Inc. John LaiMINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an...
IntelGenx Submits Response to CRL from FDA for RIZAPORT® VersaFilm®
SAINT LAURENT, Quebec, Oct. 18, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical...
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
Drs. Roger B. Cohen, Lee M. Ellis and John L. Marshall Join Actuate Therapeutics’ Scientific Advisory Board
CHICAGO and FORT WORTH, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing...
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023SOUTH SAN FRANCISCO, Calif., Oct. 18,...
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
Avicenna Academy Avicenna AcademyThe education portal provides modules, case studies and other resources related to medical cannabis for Health Care...
Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals
Chiesi USA recognized for its dedication to ensuring that employee voices are heard and valuedCARY, N.C., Oct. 17, 2022 (GLOBE...
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg...